Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DASFREE
- Sponsors Bristol-Myers Squibb
- 11 Oct 2017 Planned End Date changed from 30 Nov 2021 to 10 Oct 2021.
- 07 Aug 2017 Planned End Date changed from 1 Nov 2021 to 30 Nov 2021.
- 07 Aug 2017 Planned primary completion date changed from 1 Nov 2021 to 29 Nov 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History